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INTRODUCTION 
Leprosy is one of the very old diseases to have afflicted man. After a 
great search for the etiology, it was attributed to a bacterium Mycobacterium 
leprae by Sir Gerhard Armauer Hansen in 1873 and he remarked wryly: 
 “There is hardly anything on earth, or between it and heaven, which has 
not been regarded as the cause of leprosy; and this is but natural,since the less 
one knows, the more actively does his imagination works ” 
Leprosy is a disease with widely varied clinical manifestations and 
capable of affecting almost every organ of the body.The disease is considered 
important mainly because of its potential to cause permanent and progressive 
physical deformities.After a great struggle over many centuries, the disease has 
been brought under control. The credit goes to the advent of MDT therapy 
instituted from 1982. Most countries that were endemic for leprosy have 
achieved elimination. India achieved elimination in December, 2005.  
Though there is a drastic decline in the prevalence of leprosy among the 
endemic countries, the fall in the new case detection rate is still stable or shows 
increasing trends. The total number of new cases detected  during the year 
2011-2012 was 1.27 lakhs and children contributed 9.7% (12,305) of the new 
cases. 
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Children are susceptible to leprosy as they are to many other diseases.  
Not all the hypopigmented skin lesions are due to leprosy. Children usually 
present with single hypopigmented patch especially over the face with intact or 
impaired sensation. Clinical features of leprosy among children are confusing 
and testing of sensation in them is difficult. Unless specifically looked for, the 
diagnosis may be missed and they will manifest in early adulthood with 
disabilities. The disease in children responds well to treatment if detected in 
early stages and the deformities can be prevented. 
Above all, childhood leprosy is an indicator for assessing the endemicity 
of the disease. The high child case rate indicates the continuous spread of the 
disease in the community. It is also a measure of the efficacy of the control 
programme. 
In view of the importance of detecting leprosy early among children, 
clinical and histopathologic profile of children who were diagnosed with 
leprosy at Tirunelveli medical college hospital were analysed in this study and 
the implications are discussed. 
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AIMS & OBJECTIVES 
This is a prospective study  done on childhood leprosy patients below 14 
years of age at Tirunelveli medical college hospital with the following 
objectives 
¾ To study the incidence of childhood leprosy in Tirunelveli district. 
¾ To determine the age and sex distribution of the childhood leprosy cases. 
¾ To study the various clinical presentations, histopathological features and 
SSS status among children. 
¾ To study the incidence and pattern of nerve involvement, systemic 
involvement, reactions and deformity in the child cases of leprosy. 
¾ To find out the PB and MB proportion of child cases.  
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REVIEW OF LITERATURE 
DEFINITION:  
Leprosy is a chronic granulomatous disease mainly affecting the skin and 
peripheral nervous system and is caused by the obligate intracellular organism 
Mycobacterium leprae 1. 
Complications due to nerve damage can result in deformity and disability. 
Leprosy is a stigmatising disease. But, multidrug therapy (MDT) eliminates the 
infection and also has shown that the disease can be treated effectively and the 
disabilities can be prevented. 
LEPROSY IN HISTORY: 
 As early as 300 BC, in Hellinistic culture, created by conquests of 
Alexander the great, Hebrew Bible was translated to Greek, ‘lingua franca’.  
During this process, Hebrew word, reasonably transliterated as ‘tsaraath’, was 
translated as ‘lepra’.  But they didn’t refer to the disease; it refers to any disease 
producing scaly lesions on skin. At some time later the word lepra came into 
vogue to refer to leprosy2. 
 Leprosy is generally believed to have originated in Asia, and the earliest 
documentation of a disease mimicking leprosy comes from China and India 
during the early 6th century BC. Lowe recorded that in India, Leprosy was first 
described in the Susruthsamhita, written about 600 BC, and Chalmoogra oil was 
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used to treat Leprosy at that time3. Rastogi and Rastogi quote the Sanskrit word 
‘Kustha’ as the original name in India for leprosy. In China, Pai-Niu, a disciple 
of Confucius suffered from a disease that resembled lepromatous leprosy and it 
was known as ‘Lai, Li and Ta feng’. People believed that bones and skulls of 
Egyptian mummies could reveal even earlier evidence of the disease but it has 
not been fulfilled; the earliest paleopathological evidence to date is in mummies 
of the 2nd century BC4. 
 The disease was probably carried from India to Europe in the 4th 
century BC by returning Greek soldiers from Asia, led by Alexander the Great. 
From Greece, leprosy slowly spread throughout Europe and in Western and 
Northern Europe, the disease was most active between 10th and 15th century BC. 
The first recognisable description of leprosy in Greece  was written by Aretaeus 
of Cappadocia in the middle of 2nd century AD. Whether Alexander  brought 
leprosy to Europe and the Near east from India or whether Persians had 
introduced it into Europe during their invasions are questions with no hope of 
answer 5 . 
Noble families founded Leprosaria, hospitals for leprosy patients in 
twelfth and thirteenth centuries. Leprosy patients were legally considered as 
dead during that period and their heirs could inherit property. 
Moller Christensen’s (1961) works revealed that 80 % of the skeletons 
excavated in the cemetry of Lazar hospital at Naestved between 1250 and 1550 
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A.D. showed pathognomonic findings of leprosy. The Naestved study revealed 
that the sex incidence was equal and the majority of the leprosy cases had their 
onset in childhood 6. 
 Carl William Boeck (1808 – 75) and Daniel Cornelius Danielssen (1818-
94) are two of the most renowned leprosy experts of the nineteenth century who 
believed that leprosy was a congenital disease and not an infectious one. 
 Leprosy was conceived of as a punishment for sin. Thus the outward sign 
of Leprosy indicated a soul embroiled in sin. 
EPIDEMIOLOGY OF LEPROSY: 
Leprosy is considered important because of its potential to cause 
permanent and progressive physical deformities with serious social and 
economic consequences. 
 Despite the fact that M.leprae was discovered in 1873 by Sir Gerhard 
Henrik  Armauer  Hansen and so many researches all over the world since then, 
many of the epidemiological trends of leprosy are not clear still. In  the classical 
epidemiological triad (agent factors, host factors, environmental factors) , apart 
from the agent M.leprae  which is well described, the  entry and exit of the 
organism  from the host, its predilection for Schwann cells, the incubation 
period, are at best guesstimates. Children seem to be most susceptible to active 
infection by M. leprae but the disease manifests during adolescence or early 
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adulthood. The male to female ratio of leprosy in children is almost equal and is 
more towards males in adults7. 
GLOBAL SCENARIO: 
WHA (World Health Assembly) set out the mission to eliminate leprosy 
in 1991. i.e. the prevalence of <1 per 10,000. The goal was achieved worldwide 
in 2000 except for 14 countries. The target was then reset for those countries to 
achieve elimination at their national level by 2005. India was one among those 
14 and it achieved the goal of elimination by December, 20058. 
Global statistics according to WHO report9: 
 
No WHO region No.of new cases detected 
2010 2011 
1 African 25,345 12,673 
2 American 32,740 36,832 
3 South-east Asia 1,56,254 1,60,132 
4 Eastern Mediterranean 4,080 4,346 
5 Western pacific  5,055 5,092 
  2,28,474 2,19,075 
 
Progress since the introduction of MDT 
The combination of clear objectives, a proper technology and an effective 
implementation lead to success in the control of leprosy. There are two 
important events that aided in decreasing the global load of leprosy in the past 
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two decades. The first event was in 1981, when a WHO study group on 
Chemotherapy for leprosy put forward the use of MDT for leprosy. The second 
event was in 1991, when the 44th WHA adopted a resolution to eliminate 
leprosy by 2000 10. 
The notable achievements after the introduction of MDT are: 
 
 Almost 15 million patients with the disease were diagnosed and 
they were cured with MDT between 1985 and 2008 except for few 
relapses. 
 Prompt case-finding and early treatment with MDT has reduced the 
disability due to the disease. 
 The drugs for MDT are given free of cost in the endemic countries 
through WHO from the year 1995. 
 
The number of new cases of leprosy reported to WHO was 2, 19,075 in 
the year 2011. The new case detection rates are the highest in India, Brazil, 
Nepal, Tanzania, Mozambique and Democratic republic of Congo, Angola, 
Madagascar and the Central African Republic. India constituted 73% of all the 
new cases across the world. 
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ABOUT   NLEP: 
The National Leprosy Eradication Programme is a Health Scheme 
sponsored by Central Government. The Deputy Director of Health Services 
(Leprosy)is the head of the Programme. He is under the administrative control 
of the Directorate General Health Services, Govt. of India. The formulation of 
plan is made by the central government and it is implemented at the state level. 
The Partners of  this programme are WHO, The International Federation of 
Anti-leprosy Associations (ILEP) and few other Non-Government 
Organizations12. 
 
Milestones in NLEP 
  
• 1955 - National Leprosy  Control Programme (NLCP)    launched 
• 1983 - National Leprosy Eradication Programme launched 
• 1983 - Introduction of Multidrug therapy (MDT) in   Phases 
• 2005 - Elimination of Leprosy at  National Level 
• 2012 - Special action plan for 209 high  endemic   districts in 16 
States/UTs 
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Status in the Country: 
At the beginning of the year 2011-12, there were 0.83 lakh leprosy cases 
on record as on 1st April 2011, with a prevalence rate of 0.69/10,000. Until then 
32 States/ Union territories had attained elimination. About 530 districts 
(82.8%) out of the total 640 districts also achieved leprosy elimination by 
March 201113. 
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Trend of leprosy Prevalence (PR) and Annual New Case Detection 
(ANCDR) over the last decade are indicated in the graph below:  
 
 
 
The child case burden was greater than 10% of new cases detected in ten 
States/UTs namely (i) Andhra Pradesh 12.44%, (ii) Maharashtra 13.04%, (iii) 
Bihar 14.98%, (iv) Tamilnadu 11.56%, (v) Puducherry 14.29%, (vi) D&N 
Haveli 20.25%, (vii) Goa 12.50% (viii) Karnataka 10.76%, (ix) Kerala 11.61% 
and (x) Andaman & Nicobar Island 18.52%.  
Among the 472 (11.56 %) child cases reported in Tamilnadu in 2011-12, 
75 cases were PB cases and 397 cases were MB cases. The number of child 
cases reported with grade II deformity is 168 (35.59%).  
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AGENT FACTORS: 
Leprosy is caused by Mycobacterium leprae. These are acid fast, straight 
/ slightly curved rod shaped gram positive bacilli which can be seen single or as 
clumps or bundles on microscopic examination. They are slow growing bacilli 
and divide into two every 12 – 14 days. They do not produce toxins and have 
affinity for Schwann cells and cells of reticuloendothelial system. They can 
remain dormant in several body sites and tissues causing relapse. The organism 
is killed by boiling and autoclaving. Its susceptibility to air, cold, water, drying 
and disinfectants is uncertain14.The bacilli can survive outside the human body 
for 2-9 days depending upon the environmental conditions. The bacillary load is 
highest in lepromatous cases 15. The natural life span of the bacillus in human 
body is not known, but persisters have been isolated from patients even after 10 
years 16. 
 Mycobacterium leprae prefers cooler tissues like the skin, peripheral 
nerves, upper respiratory tract and testes and spares warmer areas. They are 
found in large quantity in the nasal mucosa and skin of earlobes, face and 
buttocks 17. 
Number of antigens has been detected in M.leprae, the most significant of 
which is the Phenolic glycolipid-1 (PGL-1) detected on serological test. The 
disease can no longer be considered as confined to human, for naturally 
acquired leprosy has been reported in the armadillo, the chimpanzee and the 
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mangabey monkey. Successful transmission of M.leprae has been observed in 
experimental animals like nine-banded armadillo and nude mouse. M.leprae can 
also be grown experimentally by injecting them into the foot pad of mice. 
However, it has not yet been shown to grow in artificial media.  
 The genome of Mycobacterium leprae was sequenced in 2000. The 
organism seems to have undergone a reductive evolution with considerable 
reduction in the gene size compared with M. tuberculosis. Nearly 50% of the 
genome is occupied by pseudogenes 18.A better understanding of the genome of 
M. Leprae may give an insight into the mechanisms by which the organism 
evades immune surveillance and which metabolic pathways it requires in the 
host cells it infects to allow the development of techniques to culture the 
organism. 
 
STRUCTURE OF M.leprae: 
It is a rod shaped bacterium which is 1-8µm   in length and 0.3µm in 
diameter, with parallel sides and rounded ends. Ultrastructural study reveals the 
bacterium has a cell wall, cell membrane, cytoplasm and a capsule. The cell 
wall is composed of the core, the inner leaflet and the outer leaflet. The core of 
the cell wall contains peptidoglycan, composed of alternating                    
N-acetylglucosamine and N-glycolylmuramate linked by peptide cross-bridges, 
which are linked to galactan layer by arabinogalactan. Three branched chains of 
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arabinan are in-turn linked to the galactan, forming along with the 
peptidoglycan layer, an electron-dense zone around M.leprae. The inner leaflet 
is a pseudolipid bilayer. The outer leaflet is composed of intercalating mycolic 
acids and phenolic glycolipids (PGL)forming the electron-transparent zone. The 
predominant lipid in the cell wall PGL-1 gives immunological specificity. 
Recent studies show that PGL-1 is involved  in  the  interaction  of  lepra 
bacillus  with  laminin  of schwann cells, suggesting  role for the lipid in 
 peripheral nerve-bacilli interactions.  The next layer is cell membrane which 
contains the two major polypeptides namely major membrane protein-I (MMP-
I) and major membrane protein-II (MMP-II).  The lepra bacillus has 3 major 
proteins in cytoplasmic extracts-a 28 kDa, a 17 kDa protein and a GroES heat 
shock protein. Outer to the cell wall the bacterium has a capsule which is 
composed of two major bacterial lipids namely 1.Pthiocercol dimycocerosate 
and 2. PGL-1, a specific glycolipid for M.leprae that is serologically active. 
 
HOST FACTORS: 
1. Age:  
 Leprosy is more commonly seen in the age group between 20 to 30 years. 
However, no age is exempt. In endemic areas the infection generally takes place 
during childhood though manifests later and in low endemic areas, the infection 
may occur in adult or later part of life. Increased proportion of child leprosy 
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cases in the population has epidemiological significance as it indicates presence 
of active transmission of the disease in the community. Age distribution of 
lepromatous cases generally shows that the disease has a later onset as 
compared with non-lepromatous cases. 
2.Gender: 
Though it affects both the sexes, males seem to be more commonly 
affected with a M: F ratio of 2:1.The gender difference is minimal among 
children below 15 years and more marked among adults. More number of male 
cases could be attributed to their greater movement for work and more 
susceptibility for contact. Males are also more active in reporting to health 
facility for seeking treatment for social reasons. 
3.Migration: 
        Due to migration of population from rural to urban areas, leprosy cases 
have increased in urban areas in recent years. The population density is very 
high (10,000 to 15,000 per sq.km), most of the inhabitants are migrants from 
distant villages ,the hygiene and living conditions are poor, breathing space is 
greatly compromised . 
Two types of leprosy carriage can be noted: a) the two way traffic, to and 
from the villages and slums, and b) one way from slums to middle class 
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localities where the population density and living conditions are different from 
those in slums. 
4. Immunity: 
        Occurrence of the disease depends on the susceptibility or immunological 
status of the individual. Immunity to the organism is disease specific. 
Immunodeficiency states like HIV and congenital immunodeficiency disorders 
doesn’t seems to increase the risk. Cell mediated immunity provides resistance 
to infection against M.leprae.  Most of the early lesions in leprosy heal 
spontaneously. Such self-limiting lesions suggest innate or acquired immunity. 
Subclinical infections also contribute to development of immunity. Some 
amount of immunity also appears likely because of infections with other related 
mycobacteria19. There is a good evidence that BCG vaccine can provide some 
protection against leprosy particularly LL.  
5.Familial clustering: 
             The occurrence of leprosy has been found more in certain clusters of 
communities and especially in family clusters. The community clusters can be 
explained in terms of environmental conditions like local mycobacterial flora to 
which all community people are exposed.  But for the family clusters it becomes 
difficult to explain whether it is due to similar environmental conditions or due 
to the close familial (genetic) relatedness. Also it has been shown that the 
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probability of finding familial occurrence of leprosy is higher in families that 
include a lepromatous patient; than in those where it does not20. 
ENVIRONMENTAL FACTORS: 
M.leprae survives well in humid environment. The bacilli survive for 
about 9 days in dried nasal secretions and for almost 46 days in wet soil at room 
temperature21. In leprosy endemic areas, the risk of developing the disease is 
more among the house hold contacts. The risk is increased by closeness and 
duration of contact. But all these factors would be operative only, if the exposed 
persons are genetically susceptible. This is supported by the observation that the 
rate of conjugal leprosy is generally low. 
SOCIAL FACTORS: 
        Leprosy is a social disease and it produces physical and psychological 
stigma as a result of the permanent deformities and even the diagnosis itself 
produces social alienation. It is generally associated with poverty related factors 
such as overcrowding , lack of education, lack of personal hygiene ,lack of 
ventilation, etc. which favours the transmission of the disease. However, it may 
affect persons from any socio-economic group. Fear of leprosy, guilt, stigma 
and discrimination associated with the disease in the community and unfounded 
prejudices regarding leprosy forces a person to hide the disease and contribute 
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to delay in seeking treatment and thus promote worsening and transmission of 
the disease. 
TRANSMISSION: 
Source of infection: 
        Man is the only natural reservoir of M.leprae and the only source of 
infection is an untreated case of leprosy. Multibacillary cases particularly 
Borderline Lepromatous and Lepromatous Leprosy spectrum are the most 
important source of infection compared to paucibacillary cases. However, all 
leprosy cases should be considered as a potential source of infection. It is now 
evident that wild animals like armadillos, mangabey monkeys and chimpanzees 
show infections with M.leprae, but they don’t seem to be a threat to humans. 
Portal of Exit: 
        Respiratory tract especially the nose is the main portal of exit of M.leprae 
from the body of an infected person. Millions of bacilli are discharged from the 
nasal mucosa of the bacteriologically positive cases during sneezing. Patients 
with leprosy harbour most bacilli in their skin, but they are shed from intact skin 
in only small numbers. However, bacilli can be shed from broken skin and 
ulcers of untreated lepromatous cases. 
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Modes of transmission: 
        Various modes of transmission of leprosy are described but it is still not 
established with certainty that only one is the major mode or all of them 
contribute. The main likely modes of transmission are: 
1.Inhalation(Droplet infection) 
2.Contact 
3.In utero transmission 
4.Transmission through ingestion (Breast milk) 
5.Inoculation following trauma 
Portal of Entry: 
        Respiratory route is the major portal of entry for the bacilli. The possibility 
of infection through the skin, particularly broken skin cannot be ruled out. 
INCUBATION PERIOD: 
        The incubation period is usually 3-5 years. But it may vary from few 
weeks to 30 or more years22. 
IMMUNOLOGY OF LEPROSY: 
Majority of the symptoms of leprosy are due to the immune response of 
the host to the organism, than due to the organism itself. We also know that the 
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individual differences in the immune activity to the bacillus are to a great extent 
controlled by genetic host factors. 
 Leprosy per se is not controlled by any HLA linked genes23. The 
susceptibility to certain types of leprosy, or, in other words, to different types of 
immunopathology certainly is linked to HLA and associated with several HLA 
alleles, particularly with HLA class II alleles. Examples are HLA-DR3 is 
associated with tuberculoid leprosy in some populations and HLA-DQ1 is 
universally associated with lepromatous leprosy24. 
Some of the recently identified genetic markers found associated with 
leprosy are 37, 38,39,40,41: 
No Gene allele, 
Chromosomal location 
Type of leprosy Function of the gene 
1 HLA-DRB1*1501, 
Ch.6p21 
Multibacillary To present  peptides for 
immune  response 
2 HLA-DQB1*0601, 
Ch.6p21 
LL,BL,TT To present  peptides for 
immune  response 
3 HLA-DQA1*0103, 
Ch.6p21 
LL To present  peptides for 
immune  response 
4 HLA-DQA1*0102, 
Ch.6p21 
BL To present  peptides for 
immune  response 
5 TNF-α 308A, Ch.6p21 Protection from 
LL,BL,leprosy per se 
Associated with high 
cytokine secretion 
6 PARK2/PACR  
Ch.6q25-27 
Leprosy per se Ubiquitin E3 ligase 
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 The heat shock protein (hsp), a 65kDa M.leprae antigen is the one which 
is studied in detail. The T cell immune response to HSP is under strict control of 
HLA class II gene. Mosmann et al (1986) study in the mouse has described two 
helper T (Th) subsets differing in their lymphokine secretion profile. The first 
subset (Th1) secretes IL-2 and IFN-gamma and the second (Th2) one IL-4, but 
no IL-2 and IFN-gamma 25. Comparing the cytokine production by T cells 
reaction with M.leprae antigens and non-mycobacterial antigens, the first 
produce a lot of IFN-gamma and no or very little IL-4 in contrast to the latter. 
Injection of IL-2 or IFN-gamma produced an increased cellular immune 
reactivity in LLHD patients with delayed type hypersensitivity reactions 2. Since 
IL-10 has the ability to inhibit IFN-gamma and IL-2 production by Th1 cells 
(Fiorentino et al 1989, Vieira et al 1991), this can be utilized as an antagonist in 
the immunotherapy of DTH reactions in mycobacterial disease 27, 28.  
 The lymphocytes perform the central part in the specific immune 
response against Mycobacterium leprae. Although M.leprae can be engulfed by 
many host cells (notably Schwann cells), they are primarily taken up by 
specialized host cells termed professional phagocytes which include the 
polymorphonuclear granulocytes and members of the mononuclear phagocyte 
system.  Presentation of peptides derived from proteins of M.leprae by class II 
expressing antigen-presenting cells (macrophages, Langerhans cells, dendritic 
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cells, activated epithelial cells) to CD4+ T cells represents the central part of 
cellular immunity in leprosy29.                            
 During persistent replication of M.leprae in the phagolysosome, the 
phagosomal membrane may become ‘leaky’, thus allowing transit of bacterial 
proteins into the cytoplasmic component to become cytoplasmic antigens. 
Antigen recognition represents an essential, though insufficient, step of T cell 
activation. In addition to this primary signal, a secondary or costimulatory 
signal is required which is delivered by interleukins 25, 30. Primary activation of 
CD4 T cells requires factors provided by the antigen-presenting cells such as 
interleukin-1 (IL-1). At later stages, CD4 Tcell activation is further increased by 
IL-2. IL-2 which is produced by CD4 T cells and at least one additional factor 
(probably IL-6) provide costimulatory signals for CD8 Tcells. In the absence of 
costimulatory signals, T cells may be tolerized. In situ analyses revealed 
abundant numbers of IFN-gamma producing CD4 Tcells in tuberculoid lesions 
and in reversal reactions which are rare in lepromatous lesions31. CD4 T cells 
from tuberculoid leprosy patients produce high levels of IFN-gamma and IL-2 
in vitro and hence belong to Th1 set, whereas T cells from lepromatous leprosy 
patients fail to produce these interleukins 32, 33, 34 . T cell numbers were 
reduced in lepromatous leprosy and the patients usually fail to respond to 
M.leprae antigens. In contrast to T cell functions, the antibody responses of both 
general and antigen specific type are enhanced in lepromatous patients. The 
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presence of antibodies along with the presence of high load of bacilli indicates 
that protection is not mediated by antibodies. 
It is likely that macrophages are activated by IFN-gamma to inhibit the 
growth of M.leprae and perhaps even to kill them35. TNF probably synergises 
with IFN-gamma in macrophage activation  36. Th1 cells which produce IFN-
gamma and thus activate anti-mycobacterial macrophage function play the 
central part in acquired resistance against M.leprae. 
CLASSIFICATION  
 Patients need to be classified in order to determine the appropriate 
treatment and also to predict the complications and prognosis. 
 There is a great need for understanding in the matter of evolving a 
common system of classification for general use. The well accepted 
classifications include Madrid, Indian classification, Ridley-Jopling, and WHO 
classification. 
I.International classification at Madrid (1953) 
It included two types and two groups. The term ‘Type’ denoted definite 
and typical clinical entities while the ‘Groups’ were less distinct non typical 
entities. The two types were lepromatous (L) and Tuberculoid (T); while two 
groups were ‘Indeterminate (I) and Borderline or Dimorphous (B). The 
morphological subtypes had been added up under each of these entities and  
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are called ‘varieties’.   
1. Lepromatous Type (L) 
Macular 
Diffuse 
Infiltrated 
Nodular 
Neuritic, pure (?) 
2. Tuberculoid Type (T) 
Macular (Tm) 
Minor tuberculoid (Tt) 
Major tuberculoid (TT) 
Neuritic, pure (Tn) 
3. Indeterminate Group (I) 
Macular (Im) 
Neuritic, pure (In) 
4. Borderline Group (B) 
Infiltrated 
Though the classification was exhaustive, yet the pre-existing objections 
could not be done away with entirely. 
II. Indian Classification: 
This was drafted on behalf of the Indian association of Leprologists (IAL) 
at almost the same time as the Madrid classification (1953) but was accepted 
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and adopted in 1955. The main objection was that the classification was not 
entirely clinical and their applicability and usefulness at all levels of leprosy 
workers was doubtful. There were 6 categories namely: 
1. Lepromatous (L) 
2. Tuberculoid (T) 
3. Maculoanasthetic (MA) 
4. Polyneuritic (P) 
5. Borderline (B) 
6. Indeterminate (I) 
II. Revised Indian Classification (1981) 
 A modification was made in the previous Indian classification. 
Maculoanasthetic leprosy (MA) was merged with tuberculoid leprosy (T). The 
resultant five group classification was called the New IAL classification of 
leprosy  
1.Tuberculoid 
2. Borderline 
3. Lepromatous 
4. Indeterminate 
5. Pureneuritic 
III. Ridley and Jopling Classification (1962) 
Though the clinical manifestations of leprosy are numerous, patients can 
be classified along a clinical spectrum. It was perfectly done coincidentally, but 
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separately by Ridley and Jopling in the U.K. and by Leiker in The Netherlands 
in 1966. This classification is based upon the fact that bacteriological, 
immunological, histopathological and clinical features of leprosy are 
intrinsically interwoven. At one end of the spectrum is the tuberculoid (TT) 
leprosy patients with a relatively high CMI and on the other end are the 
lepromatous leprosy (LL) patients without any detectable CMI against the 
M.leprae. 
The classification is as follows: 
 Tuberculoid (TT) 
 Borderline tuberculoid (BT) 
 Borderline Borderline (BB) 
 Borderline lepromatous (BL) 
 Lepromatous Leprosy (LL) 
 The advantages of this classification are that only it is easier to 
comprehend but it also helps to understand the disease in a better way. It also 
strengthens the polar and spectral concept. The main drawback is that there is 
no specific place for the indeterminate and pure neuritic leprosy in the spectrum. 
IV.WHO classification (1982) 
Paucibacillary 
Less than 5 skin lesions 
No nerve involvement or one nerve involvement 
Bacterial index of 0 
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Multibacilliary 
More than 5 skin lesions 
More than one nerve involvement 
Bacterial index ≥ 1+ 
Initially PB includes BI <2+ and BI =/> 2 in MB and it was Changed in 
1988 to paucibacillary = bacterial index of 0; multibacillary ≥ 1+ by WHO 
Expert committee on leprosy 1988 
CLINICAL FEATURES: 
 Clinical leprosy varies from the presence of an ill defined area of 
hypopigmentation that heals spontaneously to widespread involvement of 
peripheral nerves, eyes, bone, muscle and other tissues, with deformity and 
disability42 . Clinical features of the disease in leprosy are more often the result 
of host response to the presence of the bacilli than of changes directly due to 
bacillary invasion 43.The explanation lies in the infected individual's immune 
status (resistance) against the organism, and the fact that it is not a question of 
bacterial strains of varying pathogenicity which has been confirmed by Rees44. 
 It is worth remembering that a combination of skin and neural disorder is 
strongly indicative of leprosy, and the correct diagnosis can usually be made 
with the help of a pin and a scalpel 45. 
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EVOLUTION OF INFECTION AND ONSET OF DISEASE: 
 M.leprae is believed to enter the human host through the skin or the nasal 
mucosa. After a variable incubation period, in susceptible individuals a local 
lesion may be produced (primary lesion).Early single lesions in children are 
found mostly on the gluteal region, thighs, followed by those on the back and 
posterior aspects of the arms. In warm climates, children are scantily clad and 
microtrauma or insect bites may allow the entry of bacilli. Bacilli may get into 
the site of entry, they may spread via the lymphatics or there may be a 
bacillemia. Since the nerves offer a protected site, the bacilli lodging there as a 
result of the bacteremia escape elimination by the defense mechanisms of the 
body. 
 The onset is usually insidious so that it is difficult to time the sequence of 
events in the development of leprosy. Normally the incubation period is 2-
5years. It tends to vary with the type of exposure. In child contacts of 
lepromatous leprosy patients, continuously exposed to infection, it ranges from 
9 months to 6 years. 
 Duncan et al (1983) found that 2 of 38 babies born to active lepromatous 
mothers showed immunological evidence of infection by 6 months of age, and 
developed clinical leprosy at 12 and 17 months 46. 
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CASE DEFINITION: 
 At the 7th  meeting  of the WHO  Expert committee on Leprosy  in 1997, 
a case of leprosy  was  defined  as  an  individual  who  has not  completed  the 
course  of  treatment  and  has  one  or  more  of  the  three cardinal signs. 
CARDINAL SIGNS OF LEPROSY: 
 It is traditional to list these as: 
1. Diminution or loss of sensation in a typical skin lesion, or in an area supplied 
by one of the peripheral nerves typically affected in leprosy; 
2. Enlargement and / or tenderness in a peripheral nerve typically affected in 
leprosy, and 
3. The finding of acid-fast bacilli in slit-skin smears. 
FEATURES OF LEPROSY ACROSS THE SPECTRUM: 
Indeterminate leprosy: 
 Indeterminate leprosy is the first sign of the disease in 20-80% of 
patients47 .Indeterminate leprosy appears as one or a few slightly 
hypopigmented macules,1 or a few cm in diameter, with rather ill defined 
margins; in white skin they may be erythematous or coppery-red. The patient is 
usually a child .Usually there is nothing evident but a slight change in skin 
colour. Slight anaesthesia may be demonstrable but is usually absent. Smears 
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are negative, but occasionally a bacillus demonstrated within a cutaneous nerve 
.Lesions is common over the extensor surfaces of the limbs or buttocks or on the 
face. The scalp, axillae, groin and lumbar skin are usually spared48.If the lesions 
are inconclusive, and histology is not available or inconclusive, a delay in the 
diagnosis for 3 months will allow one to keep the  person free of stigma of 
diagnosis of leprosy. This type of leprosy may heal spontaneously, but about 
30% progress to a determinate  type, more often towards the lepromatous end of 
the spectrum 49. 
Tuberculoid leprosy: 
 Tuberculoid leprosy affects skin and peripheral nerves. In contrast to the 
lepromatous type, the patient with tuberculoid leprosy is likely to report early 
for medical examination. Patient may present with neural symptoms, dermal 
symptoms or both. Neural symptoms consist of pain, loss of feeling, tinglings 
and muscle weakness or paralysis. Any of these may occur singly or in 
combination. Skin lesions are single or upto 3 in number. A dermal lesion of 
tuberculoid leprosy takes the form of a well defined plaque which may be 
anywhere on the skin apart from the warm areas such as the hairy scalp, axillae, 
groins and perineum. It is erythematous on a light skin, erythematous or 
coppery red on dark skin, and has a dry surface which is often irregular and 
sometimes scaly, with raised and well-defined edges and a tendency to central 
flattening. Hair growth is deficient or absent over the lesion, and the sensation is 
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blunted (Initially, the temperature is lost followed by light touch and pain), but 
it should be noted that it is quite difficult and may be impossible to demonstrate 
impaired sensation in lesions on the face because of the extensive sensory 
supply50.Rarely the lesion is a macule, erythematous in light skin and 
hypopigmented in dark skin, with coppery or orange tint. Such macules are well 
demarcated and are dry; devoid of hair and hypoaesthetic. A thickened nerve is 
usually palpable in the vicinity of a tuberculoid lesion. A sensory nerve will be 
missed by the examiner if he does not run his finger lightly all the way around 
the edge of the lesion, for the thickened nerve is detected by feeling and not by 
sight. The extent of peripheral nerve involvement is minimal or nil. There may 
one or two in the area near a skin lesion. Nerve thickening may be smooth or 
irregular, and rarely a cystic swelling may be seen and felt in relation to a nerve 
– a cold abscess of nerve. Even rarer is calcification in a nerve. 
 In addition to testing tuberculoid lesions for sensory loss, a sweating test 
can demonstrate anhidrosis and a histamine test on a hypopigmented lesion 
shows absence of flare due to the invasion of afferent sensory nerve. Skin 
smears and nasal scrapings are negative 51 .The lepromin test is strongly 
positive. 
 True tuberculoid is usually an insignificant type of infection that will heal 
itself in a few months time without treatment52.In the Saidapet study in India in 
which untreated children were followed up for 19 years from 1937-1956 , 88% 
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of major tuberculoid and 78% of minor tuberculoid lesions healed 
spontaneously. Only 1% downgraded to lepromatous leprosy53.Tuberculoid 
leprosy seldom leads to peripheral nerve damage, nor to any disability, so one 
can say the prognosis is very good. 
Borderline tuberculoid (BT) 
Borderline tuberculoid is the most common type seen in children. The 
skin lesions of borderline tuberculoid retain more characters of tuberculoid 
leprosy. It may be present as macules or plaques or both. The number of lesions 
is greater than TT, up to 10 or 20 or more and it is asymmetrical. They vary in 
size and may be large enough to embrace the whole limb. Satellite lesions lie 
near the edges of larger lesions. Margins may be raised and well defined in part 
of a lesion, flat and vague in another. The margins may be wavy or have islands 
of extension.  Hypopigmentation, dryness pebbling and scaling are less 
pronounced than in true TT, and there is less anesthesia in the lesions. 
Peripheral nerve damage is widespread and severe. Peripheral nerve 
involvement is asymmetrical; may be irregularly enlarged, tender. Nodular 
thickening and frank abscess formation may occur. The striking feature of BT 
leprosy is the occurrence of high frequency of type 1 reaction. Nerve function 
may deteriorate rapidly and irreversibly leading to various deformities 
(Spontaneous or due to treatment / reactions). BT leprosy may present with 
large pale macules and multiple nerve involvement, it is sometimes called 
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maculoanesthetic or low resistant tuberculoid leprosy associated with liability to 
severe reaction. 
Borderline Borderline (BB) 
 The most unstable form of the spectrum that is occasionally seen in 
children. The skin lesions are more in number but not as many as in 
lepromatous leprosy. There is often a tendency to symmetry. The skin lesions 
may be macules, papules or plaques or a combination of all. They vary greatly 
in size, shape and distribution and edges may be well defined in one area and 
vague in another area. Satellite lesions are common. Geographic appearance of 
lesions and lesions with ill-defined sloping outer margin and a punched out 
center with a very well demarcated raised edge (dough nut appearance) may 
characterize this spectrum. Nerve damage is variable. It may be asymmetrical 
multiple mononeuropathy if the patient is downgrading from BT to BB or may 
be symmetrical polyneuritis if the patient is upgrading from BL to BB. Glove 
and Stocking sensory loss is unusual. 
Borderline lepromatous spectrum (BLHD): 
There is numerous skin lesions not so well defined. They occur as slightly 
infiltrated macules with copper hue, round or oval about 2-3 cms in diameter, 
with bilateral but in not so symmetrical distribution with areas of apparently 
normal skin in between. With the disease progression, papules, nodules and 
plaques may develop with sloping margin which merge imperceptibly into 
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normal skin54. Signs of nerve damage start earlier than in LL (more common in 
cases downgrading from BB). Peripheral nerves become thickened and there is 
a tendency towards symmetry with corresponding anaesthesia and paresis. BL 
patients are more prone to develop type I and type II reactions, more commonly 
ENL reaction. 
Lepromatous leprosy: 
Lepromatous leprosy may be of subpolar type (LLs) in which the patients 
were earlier in the borderline phase or polar type (LLp) in which the patient has 
been lepromatous throughout. Clinical diagnosis is based on finding typical 
early lepromatous lesions in a patient who also has some typical lesions of 
borderline type and one or more thickened nerves, with or without evidence of 
nerve dysfunction. The main reason for this subdivision of lepromatous leprosy 
is that the LLs group can rapidly regain their lost cell-mediated immunity 
during an upgrading reaction. In other words, LLp is immunologically stable 
and LLs is not. 
The signs of early LL that may precede the classical skin lesions by 
months or years are the nasal symptoms and oedema of the legs. Nasal 
symptoms include stuffiness, crust formation, and blood stained discharge. 
Oedema of the legs and ankle, always bilateral, is likely to be noted towards the 
end of the day, disappearing after a night’s rest; becomes persistent and woody 
hard at a later stage. Oedema is due to a combination of gravity and increased 
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capillary permeability, and the latter is probably due to both leprous 
involvement of capillary endothelium and damage to autonomic fibres within 
dermal nerves controlling capillaries.  
Multiplication and universal spread of the bacteria accounts for many of 
the features of the disease at the lepromatous pole. The early lesions of LL are 
small macules, innumerable in number, widely disseminated and distributed 
symmetrically. The edges are indistinct, their surface shiny and erythematous or 
hypopigmented. The early macules of LL are not anaesthetic. Lepromatous 
leprosy with infiltrated lesions presents as three distinct forms: diffuse, 
infiltrated and nodular forms. In the diffuse form, the skin has a shiny look with 
slight infiltration. Thickness of skin is most marked over the face especially 
over the forehead, earlobes, eyebrows, nose and malar surfaces. The earlobes 
are usually thickened and shiny. Thickening and nodulation of the earlobes is 
best appreciated by standing behind the patient. Loss of eyebrows is often a late 
sign of LL. Infiltrated leprosy is a more advanced stage of macular LL with 
easily visible infiltration which may be a sign of advancement of diffuse LL 
disease. Lesions are often shiny and succulent in consistency. Nodular leprosy is 
the result of progressive deterioration of the macular, diffuse or infiltrated forms 
of LL. In the early stage , the nodules appear first on the ears and later they may 
appear anywhere on the body . The infiltrated plaques accentuate the skin fold 
producing the classical leonine facies. The sensory loss is symmetrical and 
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gradually results in the typical glove and stocking anesthesia .Weakness usually 
start in the intrinsic muscles of hands and feet. The nerves are often not palpably 
enlarged and nerve conduction study may be normal early in the disease. The 
digits are swollen and tend to taper towards the tips, giving the hands and feet a 
characteristic appearance. Frequently the joints become swollen and angulated. 
Digits may shorten due to resorption of phalanges. It causes stuffy or blocked 
nose like that in coryza often followed by epistaxis. Oral mucosa may be 
involved in the form of nodules and plaques involving tongue and palate. 
Involvement of larynx can cause hoarseness of voice and stridor. Early eye 
involvement includes corneal anesthesia due to bacillary infiltration of corneal 
nerves and damage to the ophthalmic division of the trigeminal nerve. Hansen’s 
disease is one of the causes of preventable blindness55. Other ocular 
manifestations include lagophthalmos,uveitis, corneal opacity, perforation, and 
blindness. LL does not remit naturally, though in few patients it burns out itself. 
Death occurs due to the secondary infection, amyloidosis leading to renal 
failure.  
Pure neuritic leprosy: 
It is one of the forms of leprosy that is difficult to classify, and finds a 
mere passing reference in Ridley-Jopling classification of leprosy. Wade, in 
1952, was the first to recognize polyneuritic cases as a separate group56 . Pure 
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neuritic leprosy may be an early form of leprosy in evolution in some patients, 
but in others it is a distinct presentation. 
 Pure neuritic leprosy constitutes 4.3%-10.7% in most Indian studies, 
with higher frequency in South India, where it constitutes up to 18% of new 
cases 57.  Males are affected more frequently than females and patients are most 
commonly in the age group of 20-40 years. They may have symptoms for a long 
time (2.5 – 3 years) before presentation 58. Most of the patients present with 
sensory impairment, 5 – 10 % with nerve pain or deformity, and rarely as a 
nerve abscess. The deformity rate is up to 25-30%. The majority of cases are 
mononeuritic. The ulnar, median and lateral popliteal nerves are commonly 
involved. Cutaneous nerves like the sural, musculocutaneous, superficial radial 
and greater auricular nerves can be involved. 
Pure neuritic leprosy can be diagnosed on the finding of a thickened 
nerve with sensory impairment, negative slit skin smears and the absence of 
skin lesions. A nerve biopsy is diagnostic and on histology the entire spectrum 
from TT to BL leprosy may be seen. A single thickened nerve that is firm in 
consistency with a strongly positive lepromin response indicates TT-BT 
leprosy. Abscess formation may be a presenting feature and suggests 
tuberculoid leprosy. If two or more nerves are thickened and the lepromin test is 
negative or doubtful, BL leprosy may be suspected and confirmed by a nerve 
biopsy. 
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Follow-up of patients with pure neuritic leprosy shows the development 
of skin lesions in 35% of cases over 3-5 years with or without treatment.  
Histoid leprosy: 
The term ‘Histoid’ was  coined in the year 1960 by Wade59.Histoid 
leprosy is a type of multibacillary leprosy, characterized by typical cutaneous 
and/or sub-cutaneous nodules and plaques over apparently normal skin 
characteristic histopathology and specific morphology of bacilli60. It usually 
occurs in patients on Dapsone for a long time and reflects initial improvement 
followed by a relapse. It also occurs in patients who have taken inadequate 
treatment. Some believe that it is due to the drug resistance to DDS, while 
others postulate that mutant organisms, that emerge from a predominantly 
sulphone susceptible bacterial population may be responsible 61. Histoid leprosy 
is also reported in untreated patients 62 
 It presents with 3-50 cutaneous or subcutaneous nodules over the 
extensor aspects of the extremities, back, buttocks and face63. Typical lesions 
are firm, reddish, or skin coloured, dome shaped or oval papules, regular in 
contour with shiny and stretched overlying skin. The surrounding skin is 
apparently normal. They may be localized to bony prominences such as around 
the elbows and knees. The nodules are erythematous and arise from apparently 
normal skin. On the face, they can be seen in groups on the mid forehead, 
cheeks, tip of the nose, and on the chin; the ears may not be affected. In a 
39 
 
widespread eruption, the mucosa of the oral cavity, hard palate and glans penis 
may be involved. 
A slit skin smear from the lesions shows numerous AFB occurring in 
clusters, singly or tightly packed in macrophages. Most organisms are well 
preserved and are longer and have tapering ends when compared to normal 
lepra bacilli. Histopathologically, there are numerous, thin, spindle-shaped 
histiocytes with a moderate amount of cytoplasm and an oval, lightly stained 
nucleus. They may be tightly packed and arranged in whorls displacing the 
collagen bundles outwards forming a pseudocapsule. Histologically, it 
resembles neurofibroma. 
REACTIONS IN LEPROSY: 
Reactions in leprosy constitute the major complication of the disease 
which can lead to serious consequences like nerve damage and deformities. 
Leprosy reactions are immunologically mediated episodes of acute or subacute 
inflammation which interrupt the relatively uneventful usual chronic course of 
the disease affecting the skin, nerves, mucous membranes and other sites. 
Type I reactions (reversal reactions): 
Type I reactions usually occur in borderline leprosy (BT, BB and BL). It 
is mediated by type-IV (delayed type) hypersensitivity reaction. Patients may 
complain of burning, stinging sensations in the skin lesions. They may have 
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aches and pains in the extremities and of loss of strength and sensory 
perception. Increased inflammation of some or all of the pre-existing skin 
patches or plaques which become erythematous, swollen and may be tender. 
Necrosis and ulceration can occur in severe cases. Lesions desquamate as they 
may subside. Crops of fresh inflamed skin lesions in the form of plaques may 
appear in previously clinically uninvolved skin64. The pattern of these skin 
lesions are of upgrading nature clinically as compared to the existing skin 
lesions. Edema of the extremities or face, frequently accompanied by nerve 
involvement. Rapid swelling with severe pain, tenderness of one or more 
peripheral nerves is common at the site of swelling or along the course of the 
nerves. The peripheral nerve affected is usually close to the inflamed skin lesion 
or situated over the area innervated by the corresponding nerve. In severe form 
of type I reaction, nerve abscess may be formed. Tinel sign (i.e. the pressure 
exerted on the nerve gives distally a tingling pain) may be positive. Sometimes 
loss of nerve function occurs suddenly without other signs of inflammation, 
making it much less obvious – the so called ‘silent neuritis’. i.e. without 
apparent neuritis, producing claw hand, foot drop or facial palsy. Due to strong 
DTH response in type I reaction, the positivity of lepromin will be stronger in 
BT and TTs and may become positive from earlier negativity in BB and BL. 
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Type II reactions (Erythema nodosumleprosum): 
Type II reaction is an immune complex syndrome (antigen-antibody 
reaction involving complement). It is an example of type III hypersensitivity 
reaction (Gell and Coomb’s classification) or arthus phenomenon. IgG, IgM, C3 
and mycobacterial antigens are all identified at the site of ENL. The major 
clinical lesions on the skin are of erythema nodosum type; hence the term 
“Erythema nodosum leprosum“is used as an alternative term for type II 
reaction. These reactions mostly occur in the lepromatous (LL) and sometimes 
in Borderline –lepromatous (BL). Lepromatous leprosy patients with high 
bacillary load are more prone to get ENL. Risk factors include anti-leprosy 
treatment, BI >4+, patients of <40 years of age, inter current infections, trauma, 
surgical intervention and mental stress. In classical ENL reactions, no clinical 
change usually occurs in the original previous skin lesions of leprosy. There is 
sudden appearance of crops of evanescent (lasting for few days) erythematous 
tender papules, nodules or plaques variable in size. They are painful and tender 
to touch. The nodules are dome-shaped and ill-defined. The common sites of 
appearance of ENL are outer aspects of thighs, legs and face. These may be few 
or multiple. The fresh crops of ENL lesions usually appear in the evening when 
endogenous cortisol production is the lowest. After a period of 24-48 hrs. the 
lesions show a change of colour from red to bluish and brownish and finally 
dark and resolves without sequelae  in a week or ten days. ENL lesions can be 
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vesicular, pustular, bullous, and necrotic and break down to produce ulceration, 
called as erythema nodosum necroticans. In some cases, the lesions may be 
hemorrhagic resembling Lucio phenomenon. The ENL lesions subside with 
desquamation or there may be peeling of the superficial skin. Pustular lesions 
scab or leave shallow ulceration followed by scarring of the involved skin. In 
type II reactions, the systemic symptoms like fever, malaise, prostration, head 
ache, muscle, joint and bone pain, usually confining to tibia are common, may 
precede the appearance of ENL. The associated features of type II reactions are 
myositis, arthritis, synovitis, rhinitis, epistaxis, laryngitis, iridocyclitis, 
glaucoma and painful dactylitis. There may be periosteal pain (particularly in 
tibia), generalized lymphadenopathy, acute epididymo-orchitis, nephritis and 
proteinuria, renal failure, hepatosplenomegaly and anemia.  
LEPROSY IN CHILDREN: 
Clinical presentation: 
 Leprosy in the child reflects to some extent all the aspects of disease in 
the adults; with some additional features of its own. The exposed parts in 
general and limbs in specific are the commonest sites affected 65.Children suffer 
from less severe disease form and their chances of developing deformities are 
also low, mainly due to less frequent involvement of nerve trunks. Though rare 
but when it occurs,the neuritis and the possibility of ensuing deformities in 
childhood leprosy is a compounded tragedy. Prevalence of various forms of 
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disease in children is mostly derived from hospital based studies. Borderline 
tuberculoid form is the commonest, the prevalence ranging from 55-78.7% of 
all child cases in various studies. Borderline lepromatous spectrum is seen in 
approximately 7.8 % while lepromatous leprosy rates are very low, ranging 
from 1.6 – 4.9%  66,67,68   . Prevalence of indeterminate leprosy in one study was 
estimated to be 10.1%. 
 The character of skin lesions found in children, as in adults, is determined 
by the type and stage of the disease. Most cases of childhood leprosy at 
diagnosis is indeterminate or at the tuberculoid end of the spectrum. The most 
common lesions of childhood leprosy in most series are hypopigmented 
macules and raised plaques. The indeterminate form is an early presentation of 
leprosy and it may progress to either spontaneous cure or one of the subpolar 
forms. The early single lesions in children are mostly found on the gluteal 
region, face, posterior aspects of arms and hands 69. Slight sensory loss may be 
present and generally there is no peripheral nerve thickening. Any 
hypopigmented macule in the pediatric age group should arouse suspicion of 
leprosy. 
 Borderline tuberculoid leprosy in children form the most important part 
of the spectrum with regard to the number of patients seen and the severity of 
nerve damage. The lesions are greater in number than TT with less infiltration, 
less prominent margins and presence of satellite lesions. Damage to the nerves 
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is more widespread and severe. The most striking feature is the speed with 
which Type 1 reaction may occur. Nerve function may deteriorate rapidly and 
irreversibly. The cutaneous signs such as bilateral and symmetrical, 
innumerable , ill defined macular hypo anaesthetic lesions or diffuse infiltration 
of the face and earlobes and bilateral loss of eyebrows are uncommonly 
observed because of the rarity of BL and LL leprosy in children. 
 Pure neurtic leprosy presents with nerve involvement without any skin 
lesions and forms a small proportion of cases where leprosy is endemic. This 
form occurs less commonly in children than adults; and the nerve involvement 
is seen in approximately 20% of the cases. 
 Reactions are much less frequent in childhood than in adults. The lower 
prevalence of reactions and associated disabilities in children than the older 
group; is probably due to lower incidence of nerve involvement and lower 
prevalence of pure neuritic cases. Reaction is reported more frequently in 
hospital based studies, seen in approximately 25% cases 70,71,72. 
Evolution: 
 The course of childhood Hansen’s disease is unpredictable. Progression 
or regression of lesions is common, and the time course is variable. In children, 
spontaneous regression may occur in 33-75% of cases. The prognosis in 
children with leprosy on regular treatment is excellent. 
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Deformities: 
 Deformities occurring in children are most distressing both socially and 
psychologically, as they have to live their whole life with this stigma. 
Prevalence of deformities in India varies from 2.5 – 10.5%. The various factors 
responsible are increasing age of children, delay in accessing health care, more 
number of skin lesions, multibacillary disease, multiple nerve involvement and 
reaction at time of presentation and smear positivity. Children with thickened 
nerve trunk had 6.1 times higher risk of developing deformities as compared to 
those without nerve involvement. Majority of deformities are reported in upper 
limbs and only 10 % in lower limbs 73. Importance of treating the disease and 
recognizing the complications early is important to prevent visible deformities. 
LABORATORY DIAGNOSIS OF LEPROSY: 
Early diagnosis of leprosy is very important, and cannot be over 
emphasized. In the recent past, the value of laboratory tests in the early 
diagnosis has been underestimated and hence underutilized. It is heartening to 
see that there is now an attempt to recognize the value and importance of 
laboratory tests in the diagnosis and classification of leprosy.  
I.SLIT-SKIN SMEAR EXAMINATION: 
Slit-skin smear technique was first developed by Wade and Rodriguez in 
1927, described by Wade in 1935 and standardized by Cochrane in 194774. Of 
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all the laboratory tests in leprosy service, the slit skin smear examination is the 
most simple and valuable one. 
Role of Slit-skin smear examination: 
Demonstration of acid-fast bacilli (AFB) in skin smear examination 
serves several purposes: 
1. To confirm the diagnosis of leprosy, 
2. To classify the disease, 
3. To determine the infectivity of a patient, 
4. To assess the progress of the disease, 
5. To follow-up the patients on treatment. 
 When the technique was introduced, smears were obtained from multiple 
sites which included both ear lobes, both cheeks, forehead, chin, both buttocks 
and additional 6 suspicious sites. The number of sites is brought down to 4 
without compromising the value of the test because of the risk of transmission 
of HIV and to minimize the trauma to the patient. Now the routine sites are: 
1.right ear lobe, 2.right fore head, 3.chin, and 4.left buttock in men and left 
upper thigh in women. However, the active or suspicious lesion must be 
included, if the disease spectrum is closer to the paucibacillary side. In 
borderline leprosy, the bacterial load in different sites may vary considerably 
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and it is recommended that in such cases smears may be obtained from 8 sites to 
include 4 active lesions in addition to the 4 routine sites. 
The smears are stained using modified Ziehl-neelsen method and 
examined using light microscope under oil immersion (100X). The 
Bacteriological index is calculated using Ridley’s logarithmic scale as follows: 
6+: Many clumps of bacilli in an average field 
5+: 100 – 1000 bacilli in an average field 
4+: 10 – 100 bacilli in an average field 
3+: 1 – 10 bacilli in an average field 
2+: 1 – 10 bacilli in 10 fields 
1+: 1 – 10 bacilli in 100 fields. 
Morphological index is calculated as a percentage of solid staining bacilli 
after examining 200 bacilli. 
Ridley prefers his index termed SFG index in which bacilli are divided 
into three classes: ‘Solid’ (S), fragmented (F), granular (G). 
II.NASAL MUCOSAL SMEARS: 
In lepromatous leprosy, the involvement of the nasal mucosa is almost 100%. It 
has been reported that in a lepromatous patient about 10 million bacilli per day 
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can be collected from the nasal secretions75. The material is collected from the 
nasal blows first in the morning and is done very gently under the direct vision 
of the nasal cavity with good illumination. The mucosa is scraped with the blade 
and the material so obtained is processed similar to SSS. It is important to 
remember that nose may harbor acid fast saprophytes and therefore 
decolourisation should be done with an acid-alcohol decolourising solution. 
However, it is not used routinely. 
III.SKIN BIOPSY & HISTOPATHOLOGY OF LEPROSY: 
The histological features are particularly useful in the early stages when 
there is a sparsity of bacilli in skin smears. The histological changes in the skin 
in leprosy are protean and it is essential for a histopathologist dealing with skin 
biopsies from leprosy patients to be aware of these diverse manifestations. The 
special stains for AFB and nerve fibers further enhance the diagnostic yield. 
A deeper biopsy specimen containing deep cutis and subcutis is needed 
for diagnosis of leprosy  
(i)Hematoxylin – eosin stain: 
Early / indeterminate leprosy:  
 There is accumulation of lymphocytes and macrophages particularly in 
the periappendageal and perineural region. There is a focal invasion of 
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lymphocytes into the lower epidermis and dermal nerves. Epitheloid 
granulomas are not formed. Schwann cell hyperplasia is a feature and it is 
highly subjective. The diagnosis lies on finding one or more acid-fast bacilli in 
the sites of predilection. The diagnosis can only be presumptive without 
demonstrating bacilli. 
Tuberculoid leprosy: 
Large epitheloid cells are present; arranged in granulomas. They surround 
the neural and vascular structures along with the lymphocyte collection at the 
periphery. Langhan’s giant cells are absent. Dermal nerves are surrounded by 
dense lymphocyte collection and may be eroded.AFB is rarely seen. 
Borderline tuberculoid leprosy: 
 Granulomas follow the neurovascular bundles and they infiltrate the 
appendages. They have peripheral lymphocytes. Langhan’s giant cells are 
present; variable in number and are not so big in size. Granulomas are frequent 
along the vascular plexus that are superficial, but they usually do not infiltrate 
into epidermis. Erosion of nerves is typical. AFB is scanty. BI may be from 0 to 
2. IHC with S-100 demonstrates the granuloma well. 
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Mid borderline leprosy: 
 Though the macrophages are activated to epitheloid cells, they do not 
localize to form distinct granulomas. The lymphocytes are scanty. Usually, 
Langhan’s giant cells are not present. The BI is 3 or 4. There is a prominent 
dermal edema. 
Borderline lepromatous leprosy: 
There is a prominence of lymphocytes and some macrophages tend to get 
activated to form ill defined granulomas. Fibroblast proliferation especially in 
perineural region, forming an “onion-skin” appearance is typical. Foamy cells 
are not so prominent and there is no globi. BI is usually 4 to 5. 
Lepromatous leprosy: 
Usually, they have abundant cellular infiltrate and it is invariably 
separated from epidermis by a clear grenz zone of normal collagen. The 
epidermis is flattened. The infiltrate leads to destruction of skin appendages and 
may extend upto the subcutaneous fat. In early lesions, the macrophages tend to 
have abundant eosinophilic cytoplasm and they have a mixed population of both 
the solid and fragmented forms of bacilli. BI is high – 4 or 5 and they are 
packed like cigars. Lymphocyte infiltration is less, but there may be presence of 
plasma cells. With treatment and over time, bacilli degenerate and accumulate 
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within the macrophages – so called the Virchow cells – they have a foamy or 
vacuolated cytoplasm. When stained with Wade-fite stain, the bacilli are 
granular or fragmented and in chronic lesions, they are found as large basophilic 
groups. After treatment, the bacilli die rapidly and get fragmented within few 
weeks or months. But, it may take many years for the bacterial debris to get 
cleared by the macrophages. The antigens of M.leprae persist even longer and 
they are demonstrated by IHC staining. 
(ii) Job- Chako modification of Fite-Faraco Stain for M.leprae: 
AFB can be well identified using this stain.  
(iii)Gomori- Grocott Methenamine Silver stain: 
It has been found that Mycobacteria also take up the silver stain and 
appear black. Since the lipid coat of AFB is stained, even dead, fragmented and 
granular M.leprae(which usually do not take up the Fite’stain) can be visualized 
by using this method. The sensitivity is high but the specificity is very poor as 
the fibrous connective tissue and elastic tissue in the skin also take up the stain. 
So, this stain is useful in internal organ specimens and also in healed lesions of 
LL patients where the remnants may not be demonstrable using routine stains. 
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(iv)Fluorescent microscopy to detect M.leprae: 
Fluorescent method of staining is more sensitive than other routine acid 
fast stains. In a study of 56 skin biopsies from early leprosy lesions, using slight 
modification of Kuper and May’s method to obtain optimum fluorescence, 39 
showed M.leprae compared to only 25 in section stained by Fite-faraco stain for 
M.leprae76. So far, it has not been widely used. 
(v) Immunochemical staining to demonstrate Mycobacterial Antigens: 
It has been reported that the identification of early lesions of leprosy is 
enhanced by using immunohistochemical staining to demonstrate M.leprae 
antigens77,78. The diagnosis of leprosy can be confirmed by finding the 
mycobacterial antigens by immunostaining using polyclonal BCG antibodies 
and the positivity rates are higher. 
(vi) S-100 staining for Schwann cell: 
In tuberculoid and borderline tuberculoid leprosy patients, it is used to 
demonstrate the active invasion and destruction of dermal and cutaneous nerves. 
The spindle- shaped schwann cell clumps may not be easily distinguished from 
the collections of epitheloid cells. S-100 stain which selectively stains the 
Schwann cells may be used to bring out the remnants of the destroyed nerves 
lying in tuberculoid granulomas79. It should be noted that S-100 also stains 
melanocytes, dendritic cells and the cells lining the sweat ducts. 
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IV.NERVE BIOPSY: 
Used to diagnose pure neuritic cases. Usually, a sensory nerve is selected 
for biopsy. The suitable nerves include supraorbital branch of V th cranial 
nerve, a supraclavicular nerve, the greater  auricular nerve in the neck, the radial 
cutaneous nerve at the wrist, a cutaneous nerve of the forearm or thigh, the sural 
nerve at the back of the leg or superficial peroneal nerve  on the dorsum of the 
foot. The nerves usually chosen are sural nerve or radial cutaneous nerve. 
The following stains are available for study in a nerve biopsy specimen. 
1.Hematoxylin-eosin stain 
2. Job-chako modification of Fite-faraco stain for AFB 
3. Luxol fast blue stain for myelin 
4. Bodian stain for axons 
During histopathologic examination, when acid-fast organisms are 
demonstrated inside the nerves; or when granulomatous inflammation 
destroying the nerve parenchyma is seen, the diagnosis of leprosy is easily 
made. 
The few other diagnostic tests which should be mentioned although they 
are not ordinarily done in routine practice are Histamine test and the sweat 
(Iodine) test. 
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V.CYTOLOGICAL DIAGNOSIS OF LEPROSY: 
Singh et al found FNAC of skin lesions to be of value in the diagnosis of 
lepromatous leprosy. Aspirates of the nodules and plaques yielded cellular 
material and abundance of foamy macrophages and a few lymphocytes. Studies 
have also shown that FNAC is of value in pure neuritic leprosy also instead of 
nerve biopsy80. 
VI.SEROLOGICAL DIAGNOSIS: 
 Over the last 3 decades several workers have attempted the development 
of a specific serodiagnostic tests using M.leprae specific antigens and their 
epitope specific antibodies. The commonly used antigens of M.leprae are a 35 
kDa protein, a 36 kDa protein, lipoarabinomannan and phenolic glycolipid-1 
(PGL-1). Of all these, the PGL-1 based assay is most widely used and detects 
the anti M.leprae IgM antibodies. It is species specific and does not cross react 
with sera of the patients with M.tuberculosis, M.kansasii, M.avium and 
M.intracellulare. The types of serological tests used are radio immunoassay 
(RIA), monoclonal antibody inhibition test, and direct enzyme linked 
immunoabsorbent assay (ELISA). These tests can detect antibodies in serum; 
plasma, whole blood, and capillary blood collected and dried filter paper, but 
need time and expertise. The rapid and easy-to-use test suitable for use by 
peripheral health care workers include M.leprae particle agglutination test, a 
card test, a dipstick test, and a lateral flow test. The lateral flow test can detect 
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anti-M.leprae IgM antibodies in 10 minutes. Currently, the serological tests can 
neither distinguish between the past and current infection, nor they can 
distinguish between clinical and subclinical infection. The identification of new 
antigens in the future may lead to new applications for serological tests in 
leprosy 81,82. 
VII. MOLECULAR DIAGNOSIS: 
The information about molecular structure and functions has been used to 
develop molecular probes and assays for diagnosis and to assess disease activity 
in leprosy. 
Conventional PCR, reverse transcriptase PCR and nested PCR are used to 
amplify different gene stretches of M.leprae. These assays are very sensitive (1 
to 10 organisms) and exhibit a positivity of 60-75% in smear negative cases. 
Combined ethidium bromide staining of gels and hybridization further increases 
the sensitivity by 15%. Targeting M.leprae repetitive elements (RLEP) 
improves sensitivity. Effect of therapy is correlated with higher number of 
relapses. RT-PCR is more appropriate in differentiating late reactions from 
relapses. In situ protocols for PCR assays have overcome false positivity due to 
contamination in clinic or laboratory. 
Molecular methods can help in rapid direct detection of drug resistance. 
Mutations in target genes can be identified by simple molecular approaches 
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such as line probe assays and sequencing which is the gold standard. Missense 
mutations within codons 53 and 55 of the sulfone resistance-determining region 
of folP1 result in the development of high level Dapsone resistance in 
M.leprae83. Mycobacterial resistance to rifampicin correlates with changes in 
the structure of the subunit of the DNA-dependent RNA polymerase, primarily 
due to missense mutations within codons of a highly conserved region of the 
rpoB gene referred to as the rifampicin resistance determining region84,85. 
Mutations within a highly conserved region of gyrA, the quinolone resistance 
determining region, are associated with the development of ofloxacin resistance 
in most of the resistant strains of Mycobacteria 86,87. 
TREATMENT: 
 Until 1941, there was no truly effective medication for leprosy except for 
Chaulmoogra oil (Hydnocarpus) which was in use for centuries in India and 
China. Dapsone was first synthesized in 1908. Initially it was tried at doses 
similar to sulfonamides and withdrawn because of the toxic side-effect profile. 
Then, its derivative promin was tried followed by several other derivatives. 
Finally, in 1940, dapsone was tried at lower doses. To the surprise, it was very 
effective and since the early sixties, dapsone has continued to be the main 
weapon against leprosy. Clofazimine was found to have anti-leprosy effect in 
1962. The potent bactericidal drug, Rifampicin was found to be effective in 
leprosy in 1970. However, until 1982, chemotherapy of leprosy relied almost 
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entirely on dapsone monotherapy. The main problems faced were drug 
resistance, bacterial persistence and defaulting. 
 WHO recommended multi drug therapy in 1982 for both PB and MB 
patients. The reasons for the introduction of MDT are: 
 To reduce the incidence of post-treatment relapse 
 To prevent drug resistance 
 To reduce the side effects 
 To increase the cost effectiveness 
 To  shorten duration of treatment  
MDT is issued free in Blister packs with each pack contains drugs for 1 
month. All we have to do is to decide which course of treatment (PB or MB) the 
patient needs based on WHO criteria and ensure if they are taking the drugs 
regularly. 
 
TREATMENT REGIMEN FOR PB PATIENTS: 
FOR ADULTS: 
MDT FOR PB LEPROSY 
MONTHLY DOSE 
(supervised) 
C.Rifampicin 600 mg 
T.Dapsone 100 mg 
DAILY DOSE T.Dapsone 100 mg 
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FOR CHILDREN: 
PB-MDT   AGE <10 YRS AGE 10-14 YRS 
MONTHLY DOSE 
(mg)-supervised 
C.Rifampicin 300 450 
T.Dapsone 25 50 
DAILY DOSE(mg) T.Dapsone 25 50 
 
 The monthly dose should be given under supervision. The course of 
treatment is given for 6 months. It must be completed within 9 months or less. 
 
TREATMENT REGIMEN FOR MB PATIENTS: 
FOR ADULTS: 
MDT FOR MB LEPROSY 
Monthly dose (supervised) 
C.Rifampicin 600 mg 
C.Clofazimine 300 mg 
T.Dapsone 100 mg 
Daily dose 
T.Dapsone 100 mg 
C.Clofazimine 50 mg 
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FOR CHILDREN : 
 
The monthly dose is taken at the start of treatment (Day 1) and then every 
28 days for 12 months. The daily dose is taken every day for 12 months. It must 
be completed within 18 months or less. 
Earlier, MB patients were recommended to be treated for 2 years or till 
the skin smear becomes negative, whichever was later. In view of reported low 
relapse rates; recommendations were made to stop therapy after the completion 
of 24 monthly doses given in a maximum of 36 months. Then 2 years MDT also 
is considered too long from the operational point of view. In view of the 
changed definition of MB cases, low relapse rates, and demonstration that 
treatment with dapsone and clofazamine daily for 3-6 months was able to kill 
almost all viable bacilli- meaning that all spontaneously occurring rifampicin 
                         MB-MDT  AGE <10 YRS AGE 10-14 YRS 
MONTHLY DOSE 
(mg)-supervised 
C.Rifampicin 300 450 
C.Clofazimine 100 150 
T.Dapsone 25 50 
DAILY DOSE(mg) T.Dapsone 25 50 
 C.Clofazimine 50(twice weekly) 50(alternate days) 
60 
 
resistant mutants are likely to be eliminated by this therapy-a treatment duration 
of 12 months has been recommended by WHO in 199788.  
The newer drugs used in the treatment of Leprosy are Fluoroquinolones, 
Minocycline, Clarithromycin, Ansamycins (Rifabutin, Rifapentine, R-71-1, R-
76-1), Fusidic acid,etc.  
 
NEWER DRUG COMBINATION: 
ROM therapy: 
A single dose (Rifampicin, Ofloxacin and Minocycline) has been tried for 
single skin lesion (SSL). It has also been trialed for PB cases. Even this regimen 
has already been adopted and recommended by the National Leprosy 
Elimination Programme in India for single lesion but not recommended these 
days as relapses are beginning to be reported in patients treated with single dose 
ROM 89. 
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MDT- Blister packs 
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MATERIALS AND METHODS 
 
INCLUSION CRITERIA: 
1. Children aged 0 – 14 years 
2. Both sexes 
3. Cases who are newly diagnosed as Hansen’s disease during the study period 
4. Both the direct and referred cases from the PHC s, ULC s and other hospitals 
in Tirunelveli district. 
 
EXCLUSION CRITERIA: 
1. Children> 14 years 
2. Children who have taken anti-leprosy treatment in the past in the form of 
monotherapy or as MDT. 
Our study was a hospital based open prospective study conducted at 
Department of Dermatology in Tirunelveli Medical college hospital on Newly 
diagnosed childhood cases of Leprosy (includes the cases directly attending the 
OPD and those who are diagnosed in the field and referred to hospital) aged 0 – 
14 years to study and analyse the clinical profile and Histopathology in every 
aspect during the period from September 2010 to October 2012. 
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A detailed history is elicited from the patient’s attendant usually a parent 
regarding the presenting complaints, history and duration of the presenting 
illnesses, past history of similar and associated illnesses, family history of 
leprosy, treatment details including vaccination particulars especially of BCG, 
socio-economic status was taken 
The complete physical examination was conducted including built. 
nourishment, lymphadenopathy, pedal edema, vital measures  of pulse and 
blood pressure , examination of systems including  cardiovascular , respiratory , 
central nervous system and per abdominal palpation was conducted. Gait, Facial 
features and visible deformity of leprosy if any were noted. 
A thorough dermatological examination of the skin lesions regarding 
number of skin lesions, morphology , site , size , shape, colour,surface , margins 
, sensation , trophic changes viz. presence or absence of hair&sweating, satellite 
patches and lesional tenderness were recorded. Examination of the peripheral 
nerves done with palpation of supraorbital nerve, supra trochlear nerve ,infra 
orbital nerve, greater auricular nerve , supraclavicular nerve , ulnar nerve , 
radial nerve, median nerve , radial cutaneous nerve , lateral popliteal nerve , 
posterior tibial nerve and sural nerve were done to look for the enlargement , 
tenderness , symmetry, consistency , nodularity , abscess formation and noted. 
Examination of the sensory system done along the course of the nerve 
and also for glove and stocking pattern with the modalities of temperature using 
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hot and cold test tubes , fine touch with a wisp of cotton , and pain with the help 
of a needle. Functions of the muscles of the forearm, hand, leg and feet were 
assessed by voluntary muscle testing (VMT). The six grades for VMT using 
Medical Research Council (MRC Scale) are as follows: 
Grade 5: Normal power (with full resistance) 
Grade 4: Muscle contraction against slight resistance but power 
subnormal 
Grade 3: Movement possible without resistance   
Grade 2: Active movement when gravity is eliminated 
Grade 1: Flicker of movement 
Grade 0: No movement 
Genitalia of both the male and female patients were inspected and 
testicular size, consistency, sensation and tenderness if any were also noted.  
Deformity was noted and graded using WHO grading. 
Slit skin smear examination was done at our OPD using an 11 size blade 
and the smear is stained by modified acid fast stain. The smears were taken 
from 4 routine sites (Right earlobe, Right forehead, and chin, gluteal region in 
males and upper lateral thigh in females) and 2 – 4 from the lesions depending 
upon the patient 
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Bacteriological index was calculated using Ridley-Jopling scale. 
Morphological index was also calculated as the percentage of solid 
staining bacilli, calculated after examining 200 red staining elements lying 
singly. 
SSS repeated at 3 months, 6 months (in MB cases) and before RFT in all cases. 
An elliptical incisional skin biopsy was taken from the skin lesion. The 
specimen was processed and stained with Hematoxylin and eosin and also with 
Fite - Faraco’s method. The Histopathologic features in each case were noted. 
The diagnosis of leprosy is made by correlating all the three features 
namely clinical features, SSS and HPE examination 
Baseline blood investigations were done which included complete 
hemogram, Renal function tests, Liver function tests and Urine routine 
examination was done 
Patients were categorized into PB and MB based on WHO criteria and 
treatment was given with either Paucibacillary or multibacillary blister packs 
(fixed drug dosages and combinations available according to their age) provided 
free of cost to the patients under NLEP project. 
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The cases were followed up every 3 months to look for any new lesions, 
new nerve involvement and signs of reaction during treatment. Sensory testing 
and muscle power were assessed during every visit. Blood investigations were 
also repeated during each visit. 
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Table 1: Comparison of Age Distribution with  Gender : 
Age in years Male Female Total 
0-5 0 0 0 
6-10 5 (45.5%) 5 (62.5%) 10 (52.6%) 
11-14 6 (54.5%) 3 (37.5%) 9 (47.4%) 
11 8 19 
 
As depicted in  Table 1 & chart 2: 
Out of the total 19 children in our study, 10 children (52.6%) belong to 
the age group of  6-10 years and  9 children (47.4%) were in  11 to 14 years 
group .There  were no cases detected  below 5 years of age. Sexwise, 11  
patients  (57.89%)  were  males  and  8  children (42.11%)  were of female 
gender. 
In the age group of 6 to 10 years , the number of males and females are 
equal whereas in higher age group of 11-14 years,  there is a male 
preponderance. 
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Table 2: Comparison of presenting complaints of the study 
population with respect to gender  : 
Presenting 
complaints 
Male n=11 (57.89%) Female n=8 (42.11%) 
Total 
n 
 
% 
 
N 
 
% 
 
n % 
Deformity  1 5.3% 0 0 1 5.3% 
Patches 2 10.6% 4 21.1% 6 31.6% 
Screening 7 36.8% 4 21.1% 11 57.9% 
Trophic Ulcer 1 5.3% 0 0 1 5.3% 
 
Of the 19 cases in our study, 11 children(57.89%) were  diagnosed  
during  screening  which  includes  both  family screening  of contacts  of 
already  diagnosed  patients  and  also through  other  screening  camps. Rest of 
the  8  children (42.11%)  presented  themselves  to  medical  care , 6 children 
(75%)  were brought  with  patches  and  1 child (12.5%)  with  visible 
deformity  and  trophic  ulcer  each. [Depicted in table 2 & chart 3 ] 
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Table 3: Contact status of children with respect to gender 
distribution 
Nature of Contact 
No. of Patients Percentage (%) 
Male Female Total Male Female Total 
No 6 6 12 31.5% 31.5% 63% 
Household contact 3 2 5 15.8% 10.5% 26.3% 
Neighbourhood 
contact 2 0 2 10.5% 0 10.5% 
Total 11 8 19 57.9% 42% 100% 
 
Among the 19 children, 7 had a positive history of contact with known 
leprosy patients. They are analysed in table 3 & chart 4. Of  these  7  children , 5  
children  had  house hold  contacts  and  2  had  contact with cases  in  the  close  
neighbourhood  ( in the next  house ). Except for  the  2  children  who  had  a  
contact  with  the  neighbourhood  PB  cases,  all the  other  children’s  contacts  
were  multibacillary  cases  .  All were LLHD with highly positive smears. 
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Table 4 : Analysis  of the number of skin lesions at presentation: 
No. of Skin 
Lesion  
Male  
n=11 (57.89%) 
Female  
n=8 (42.11%) 
Total 
n  % n % n (%) 
1 8 42.1% 3 15.8% 11 57.9% 
2-5 3 15.8% 1 5.3% 4 21.1% 
>5 0 0 4 21.1% 4 21.1% 
 
Regarding the number of skin lesions, majority of the patients (57.89%) 
had a single skin lesion. There are 4 children (21.1%) with 2 to 5 patches. The 
number  of  children  with  more   than  5 patches  were  4 (21.06%)  in  the  
study. 
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Table 5: Analysis of morphology of skin lesions at presentation: 
Morphology 
No. of patients With nerve 
involvement 
N (%) Male 
 
Female 
 
Total (%) 
Single  Patch 5 5 10(52.6%) 5(50%) 
Multiple patches 3 2 5(26.3%) 2(10.5%) 
Only Plaques 2 0 2(10.6%) 2(100%) 
Patches & Plaques 1 1 2(10.6%) 1(50%) 
Total 11 8 19 10(52.6%) 
 
In the study, 16 children (84.21 %) had patches at the time  of  
presentation. Of them, 10 children (52.6%) had single patch and 5 (26.3%) 
children had multiple patches. 50% of the children with single patch had nerve 
involvement. The plaques were the only morphology in 2 (10.6%) children and 
both had nerve involvement. Out of the 5 children (26.3%) with multiple 
patches, 2 had nerve involvement. Only 2 children had more than one 
morphology of lesions (Patches & Plaques).[Table 5 & chart 6]  
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Table 6 : Analysis of clinical spectrum among children: 
 
Clinical 
spectrum 
Male  
n=11 (57.89%) 
Female  
n=8 (42.11%) 
Total Smear 
status 
6-10  
years 
11-14  
years 
6-10  
years 
11-14 
years 
Indeterminate 0 0 2 (25%) 0 2(10.5%) N 
TT 1 (9.09%) 0 0 0 1(5.3%) N 
BTHD 4 (36.36%) 6(54.5%) 3 (37.5%) 3 (37.5%) 
 
16(84.2%)
 
N 
BLHD 0 0 0 0 0 N 
BB 0 0 0 0 0 N 
LL 0 0 0 0 0 N 
N= Negative. 
 
Table 6 & chart 7 shows that the most common clinical spectrum in 
children is BTHD  (84.2%) in this study followed by Indeterminate type 
(10.5%) and TT constitutes only 5.3 % of the children. There was no child with 
BB,BL or LL spectrum. 
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ANALYSIS OF NERVE INVOLVEMENT: 
Among the 19 cases, 10 (52.6%) children had nerve involvement. 
Table 7: Analysis of Pattern of nerve involvement in children with nerve 
involvement 
No Age/ 
Sex 
No.  
of 
nerves 
TRUNK NERVES CUTANEOUS NERVES Defor
mity 
Ulnar  median Radial LPN PTN STN RCN Sural Others 
1 11/M 3 + B/L - - - - - + Lt - - Lt.Ulnar 
claw 
2 10/M 3 +Lt - - +Lt +Lt - - - - Lt.Claw 
toes 
3 8/F 6 +B/L - +B/L +Lt +Lt - - - - - 
4 12/F 1 +Lt - - - - - - - - - 
5 11/M 4 +Lt - - +Lt +B/L - - - - - 
6 9/F 2 +B/L - - - - - - - - - 
7 12/M 3 +Lt - - - +B/L - - - - - 
8 10/M 3 +Rt - - - +Lt +Lt - - - - 
9 10/M 1 - - - +Lt - - - - - - 
10 10/F 1 +Lt - - - - - - - - - 
 
Peripheral nerve enlargement was seen in 10( 52.63%) children in the 
study[Table 7].The most frequently involved peripheral nerve trunk is Ulnar 
nerve; in 90 % of children with nerve involvement. The second common nerve 
affected is posterior tibial nerve and third being lateral popliteal nerve in this 
study. 
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Table 8: Analysis of PB and MB proportion with respect to age and gender 
distribution of the children: 
The total numbers of PB children are 11 (57.9%) and MB children are 8(42.1%) 
Age 
Male n=11 (57.89%) Female n=8 (42.11%) 
PB  
(n=5) 
MB  
(n=6) 
PB  
(n=6) 
MB  
(n=2) 
6-10 3(27.3%) 2(18.15%) 3(37.5%) 2(25%) 
11-15 2(18.15%) 4(36.4%) 3(37.5%) 0 
 
Table 8 & chart 8 depicts that the incidence of PB cases (57.9%) is more 
than the MB cases (42.1%) in the study. Among the male children, MB child 
constitutes 54.5% and PB child constitutes 45.4%. Whereas in females PB child 
cases (75%) clearly out numbers the number of MB Cases (25%) 
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 SSS was negative in all the cases in the study. 
 In this study, the histopathological examination was correlating with the 
disease per se in all the patients. The correlation between the clinical 
spectrum and the histopathology was done in all cases. Both the children 
with  indeterminate type of leprosy  had a correlating 
histopathology(100%) . The patient with tuberculoid type clinically did 
not show any evidence of well formed granuloma. The rest of the patients 
were of Borderline tuberculoid type. Among the 16 of them, one case 
showed well formed granuloma.  Others showed  scant periadnexal 
lymphohistiocytic infiltrates. 
 No evidence of systemic involvement were noted during the study. 
 Type I reaction was noted in a male patient with Borderline tuberculoid 
leprosy. Type II reaction was not encountered. 
 Deformity was noted in two patients (10.5%). Both were male children. 
One had ulnar claw hand and the other child had claw foot. 
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DISCUSSION 
 The proportion of childhood leprosy among new cases in Tirunelveli 
district  was  5.7% (19 children) during the period of study [Chart 1]. Of these 
19 children, 7 children presented directly to the medical college hospital 
whereas remaining 11 were detected in the field through camps and referred to 
the medical college hospital.  
 Childhood leprosy was maximum  in the age group of 6-10 years in our 
study[Table 1] which is consistent with the study of Selvasekar et al,199990 and 
Keelar et al, 198591. Childhood leprosy was mostly seen in age group of 5 – 14 
years in a study by Dayal et al, 199092. 
Child cases in our study showed a slight male preponderance with the 
male to female ratio being 1.6 : 1 as shown in Table 2. Significant  male 
preponderance was seen in studies done by Sandeep Sachdeva et al93 ,2010(2:1)  
in Jawaharlal medical college at Aligarh and Singal et al 94 ,2011 in GTB 
hospital at Delhi. As per literature, there is a male preponderance in the disease 
in adults but the gender difference is least in children. This study correlates with 
the above fact. Males and females were equal in the age group of 6 to 10 years 
in the study but there was a male preponderance in 11 to 14 years age group. 
In our study, the youngest case reported was a 7 year old male child  
comparable to the  reports of 6 years in the  studies conducted at Eastern Nepal 
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by Deb Burman et al68,2003 and a peripheral hospital in Andhra Pradesh by AG 
Rao et al95 ,2009.The disease in infants was very high before the advent of 
MDT. Brubaker et al96,1985 reported 91 infants with leprosy from the records of 
US armed forces institute of leprosy and a correspondence survey. Many such 
reports had been made from India also with mother contacts in the last century. 
It has declined in the past decade since MDT is being given safely to the 
pregnant and lactating mothers. The incidence of leprosy in children of lower 
age groups including infants have decreased drastically now a days and only 
very few cases have been reported sporadically. Moorthy et al 97(2006) have 
reported leprosy in an 8 month old infant from Blue Peter research centre at 
Hyderabad.   This reduction  is the result of the effective national control 
programme . 
Incidence rate among members of leprosy affected  families living under 
the same roof has been shown to be higher than in the general population 
(Jesudasan et al 1984)98. In this study  , 7 ( 36.8 %)children had a history of 
contact with Leprosy patients as shown in Chart 4. Of these, 5 children had 
history of family contact and the 2 others had contact in close neighbourhood 
[Table 3].  The family contacts were all at the higher spectrum in our study - 
fathers with LLHD under MB regimen. In a study done at Hyderabad by  Jain et 
al(2002)99 ,  history of contact was present in 38.8% of children with 95 % of 
them having index case in the family. 65% of the contacts were MB in that 
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study. In another retrospective  study done at Jawaharlal Nehru medical college 
in Aligarh by Sachdeva et al93,35% of children had house-hold contact with 
leprosy. All of them are invariably of MB type. Hence ,this study correlates well 
with the above mentioned studies. 
 Although a pivotal role of close contacts has been documented by several 
researchers, a few similar studies have shown that clinical leprosy develops only 
in susceptible persons after a contact with the patient. They opine that 
susceptibility is inherited and may be transmitted through successive 
generations without the appearance of clinical leprosy93. But the hereditary 
relationship within them were not clear. The chance of acquiring the disease is 
directly related to the closeness of the contact and the genetic relatedness 
between them. The possible reasons for the incidence among families may be 
chronic skin to skin contact, through droplet infection. HLA predisposition 
among families also contribute to the occurrence of disease. Whatever be the 
etiology this high level of family contact of the Hansen’s disease in these 
children strengthens the necessity of strategy of screening children in leprosy 
affected households. There was no mother contacts in this study. 
In this study, 11 children (57.89%) presented with a single skin lesion 
[Table 4].  It  correlates with the previously published studies by Selvasekar et 
al93, 1999, Nadkarni et al100 ,1988& Kumar et al,1989101 where  single lesions 
were most frequently seen. The cutaneous signs like bilateral and innumerable 
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or diffuse involvement of skin uncommonly observed because of the rarity of 
BL and LL leprosy in children. There is no case of BB, BL or LL type in this 
study. 
The morphology of the lesions had  varied in different studies (Prasad et 
al,1998; Ganapthi et al,1976)102,103. Hypopigmented hypoanasthetic patches  
were the most common type of lesions in our patients (78.9%) similar to the 
study by AG Rao et al,2009 (68.8%)95.  
Borderline tuberculoid  Hansen’s disease  is the most common  type of 
leprosy  in this  study (78.94%) as shown in Table 6. Similar observations were 
noted in the studies by AG Rao et al,200995 (71.88%), Singal et al94,2011 
(70.3%) ,  Kumar et al,1989101 (57.7%), and Jain et al ,200299 (66.3%). 
More number of the skin lesions were on the exposed parts of the body, 
face, limbs in our study. Such observations were in concurrence  with those  
noted by Jain et al 99(2002) , AG Rao et al95(2009)  and Sehgal and Chaudhary 
(1989)104. This can be explained by the fact that in warm climates, the children 
are scantily clad and microtrauma or insect bites may allow the entry of bacilli . 
The prolonged viability of M.leprae  may facilitate such entry (Desikan and 
Sreevatsa ,1979).However  majority of the lesions were observed on the gluteal 
region in a study by Ganapati et al (1976). 
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Peripheral nerve enlargement was seen in 10 (52.63%)  children in the 
study [Table 7]. The study by Deb Burman et al 68,2003 had almost same 
statistics with the nerve involvement being 55%.  Similar  frequency of nerve 
involvement was documented by Kaur et al,1991(60%)105. Higher incidence 
was reported by Singal et al,201194 (70%). Of the 10 children , 3 (30%) had 
mononeuritic and 7 (70%) had polyneuritic involvement. Among  the three 
mononeuritic cases, 2 had ulnar nerve involvement and 1 had posterior tibial 
nerve involvement. 
The most frequently involved peripheral nerve trunk is Ulnar nerve in our 
study incident in 9 children (47.36% of the total children). Deb  Burman  et al68, 
2003  also reported Ulnar nerve as the most common nerve involved among 
children in his study. Many of  the studies done previously have not discussed 
about the individual nerve involvement. Among the children with nerve 
involvement, Ulnar nerve was involved in 90%.The second common nerve 
affected is posterior tibial nerve and third being lateral popliteal nerve in this 
study. 
Reactions  in children is a rare entity. In our study, 1 child (5.26%) 
developed type I reaction. Most of the studies done in childhood leprosy 
reported comparable incidence. To state a few are the studies done by I Horo et 
al1062010 (4.63%), Sandeep Sachdeva et al93,2010 (1.36%). There are no cases 
of  type II reaction in our study. 
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Smear positive cases are considered as rare in children (Nadkarni et al , 
1991; Keelar et al,1985). In our study no case was found to have positive slit 
skin smear [Table 6]. On contrary to our study, the  manyother  studies have 
shown significant positivity reports (AG Rao et al,200995 (25%) ; K Deb 
Burman et al68,2003(30%).) The  variation is due to more number of cases at the 
higher spectrum (BB,BL,LL) in other studies. In our study, only 1 child was in 
BL spectrum. All the other children were of I,TT and BT type and SSS may not 
always be positive in them. 
The Histopathologic examination of the skin lesions was consistent with 
Hansen’s disease in all of our patients (100%). The 2 children with 
Indeterminate type of leprosy had histopathologic features correlating with the 
diagnosis. Though all the other cases are of TT and BT type clinically, well 
formed granuloma was evident only in 2 cases. All the other cases had  
collection of macrophages and lymphocytes at the sites of predilection for 
Hansen’s disease – in the perineural, peri-appendageal region. Altogether, this 
study showed a histopathological correlation in about 21% of cases. High 
correlation was observed in a study conducted by Singal A et al94,2011. Few 
other studies had a relatively lower clinicopathological correlation which 
includes the study done by  Bhushankumar et al,200067(60.6%) . Another study 
done by AG Rao,200995 et al showed comparable low correlation of 37.5%. 
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Deformities and disabilities  are  not so commonly encountered in 
children when compared to adults. In our study, 2(10.53%) of the children had 
grade II deformity [Table 7]. Similar incidence of deformity was reported in the 
study done by Kar and Job,200573 (10.5%) and Singal A et al,201194 
(12.8%).The study done by AG Rao et al95,2009 revealed a very low incidence 
of 3.12%.Both of the children were males in the study. 
Based on WHO criteria, 8 children (42.10%) in our study were of the 
Multibacillary type of leprosy and 11 (57.89%) of our children were of 
Paucibacillary type as shown in Table 8. PB and MB cases were almost equal in 
our study. Deb Burman et al,200368 and Singal et al ,201194 showed similar 
observations where as the Paucibacillary leprosy was the commonest type in 
various studies ( Prasad et al,1998102; Selvasekar et al , 199990 ; Kaur et al, 
1991105). This may be related to the varying study period and sample size. 
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SUMMARY 
 The following are the implications derived from this  prospective study 
done in  the childhood Leprosy patients of age upto 14 years over a period of 2 
years : 
¾ The Incidence  of childhood leprosy  in  Tirunelveli district is 5.7%   in 
the study period. 
¾ The most common age group affected is 6 to 10 years (52.63%). There 
was a slight male preponderance with male to female ratio being 1.6:1. 
The youngest case was a 7 year old male child. 
¾ A significant proportion (36.84%) had contact with leprosy patients 
especially within the family. 
¾ In this study, 47.4% of the children presented with only skin lesions and   
53.6% with skin and nerve involvement. There was no case of pure 
neuritic leprosy. 
¾ Histopathological examination was consistent with Hansen’s disease in 
all the cases. Clinico-pathologic correlation was noted in 21% of children 
whereas others showed features of early Hansen’s disease. 
¾  Borderline tuberculoid type is the most common type noted.  No cases of 
BB,BL or LL were encountered. 
¾ The nerve involvement was seen in 52.6% of children. Ulnar nerve was 
the most commonly  involved. 
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¾ Systemic complications were absent  in the children in this study. 
¾ Type I reaction was incident in 5.3% of children in the study period. 
There was no case with type II reaction. 
¾ Grade II deformity was noted in 10.5% of children. 
¾ In this study,57.9% of children were of  Paucibacillary type and 42.1% 
were of Multibacillary type. 
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CONCLUSION 
Leprosy continues to be an important health problem in children. Though 
the incidence of childhood leprosy has become low, considerable proportions of 
children are presenting to health care at a late stage with deformities which 
indicates reluctance either to come forward or an inadequate detection which 
may be related to unawareness. Deformities occurring in children are more 
distressing both socially and psychologically, as they have to live their whole 
life with this stigma. It is imperative that our goal should be to bring all cases of 
leprosy in children under treatment at the earliest possible stage. Childhood 
leprosy reflects the status of disease control in the community and in turn 
efficacy of the control programme .Awareness should be raised in the society by 
all means including the media and the health services. Parental education, 
counselling, screening of household contacts of leprosy patients and school 
surveys form an integral part of early detection and treatment to achieve the 
goal of eradication of leprosy. 
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DISSERTATION PROFORMA 
CLINICO-PATHOLOGIC STUDY OF CHILDHOOD HANSEN’S 
DISEASE 
 
1. Patient name 
2. Age 
3. Sex 
4. Father/guardian name 
5. Address 
6. Informant  
7. Directly attending OP/Referred case 
8. Referred from 
9. Presenting complaints and duration 
10. H/o Presenting illness: 
Elaborating the presenting complaint 
H/o Patch 
H/o sensory disturbance 
H/o muscle weakness 
H/o Pain along nerves 
H/o fever 
H/o Ulcers & blisters 
H/o joint pain 
 
 
H/o Epistaxis 
H/o Nasal stuffiness 
H/o Slipping of foot wear 
H/o swelling of hands and feet 
H/o nodules over skin 
          H/o Pain in and around eyes 
H/o Redness of eye 
H/o Photophobia 
      10. Past History 
 H/o Antileprosy treatment 
 H/o juvenile diabetes 
 H/o Hypertension 
 H/o allergy / asthma 
H/o contact with hansen’s patient 
11.Family History 
 H/o similar illness in other family members 
 H/o proved Hansen’s disease patient in the family 
 
12. Treatment History 
 
13. Socio-economic History 
 Standard of living 
 
 
 Sanitation facility 
 No.of  family members 
 Percapita income 
14. General Examination 
 Level of conciousness / orientation 
 Whether the child is comfortable  
 Examination of physical signs  
  Anemia 
  Jaundice 
  Cyanosis 
  Clubbing 
  Generalised lymphadenopathy 
  BCG scar 
Vital signs – PR  
 BP  
 RR 
 
15. Examination of systems 
  Cardiovascular system 
  Respiratory system 
  Per abdomen 
  Central nervous system 
 
 
16. Dermatological examination 
 I. Examination of patches: 
  Number 
  Size 
  Shape 
  Margin 
  Surface- sweating , dryness , hair loss 
  Symmetry of  patches 
  Cutaneous nerves surrounding the patch 
 II. Examination of the Nerves ; 
 Nerves examined: 
 NERVE RIGHT LEFT 
Supraorbital  N   
supratrochlear N   
Greater auricular N   
Radial N   
Median N   
Ulnar N   
Common peroneal N   
Posterior tibial N   
Supraclavicular N   
Radial cutaneous N   
Sural cutaneous N   
 
 
 
 Description 
  No.of Nerves involved 
  Size of the nerve 
  Symmetry 
  Tenderness 
  Extent of enlargement 
  Nodular thickening / Abcess formation along the nerve 
III. Examination of sensory system: 
 
 
 
IV. Examination of motor system 
 
 
V.Examination of other features: 
 Ear Lobe thickening 
 Superciliarymadarosis 
 B/L Gynacomastia 
 Pedal edema 
 Trophic Ulcer : 
 
 
 
 
 Lymph nodes: 
 Hepatospleenomegaly: 
 
Diagnosis: 
 
 
 
Slit Skin smear: No: 
Report: 
 
 
Skin Biopsy: No: 
Report: 
 
 
Treatment regimen : 
 
Investigations: 
 
 
 
 
 
 
 
FOLLOW –UP: 
DATE CLINICAL FEATURES ADVICE 
   
   
 
 
 
 
 
